EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis

Kayleigh Evans, Roland Seifert

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04443-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Kayleigh Evans und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 , Hannover, Germany. Hauptthemen laut MEDLINE: Drug Repositioning, Cardiac Glycosides, Sodium-Potassium-Exchanging ATPase, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As Na + -K + -ATPase (NKA) inhibitors (‘cardiac glycosides’) have declining rates of prescriptions because of their narrow therapeutic window, high toxicity and questionable clinical efficacy in cardiological indications, the question arises what the future of these drugs entails. In this paper, we researched and analysed newer uses of these drugs outside of their traditional indications, also referred to as repurposing. On ClinicalTrials.gov, we analysed the trials on NKA inhibitors including the scientific value of published trials. Of 306 trials to be analysed, only 40 were for repurposed use, of which 17 had a publication. Malignant diseases and foetal demise for late abortion are the most prominent indications. However, the quality of the clinical studies analysed was far from satisfying. Not a single study provided compelling evidence for a new clinical indication of NKA inhibitors at clinically relevant drug doses. NKA inhibitors could still have a future, specifically as part of oncological treatments. Different molecular mechanisms of action beyond NKA inhibition may be relevant for this use. However, further research is still required to see if in vitro effects can be translated to in vivo as well, which is the major bottleneck in repurposing NKA inhibitors in their narrow therapeutic window and high toxicity, unless specifically exploited in foetal demise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningCardiac GlycosidesSodium-Potassium-Exchanging ATPaseEnzyme InhibitorsHumansAnimalsClinical Trials as Topic

Stichwörter der Autor:innen

Cardiac glycosidesDigoxinNKA inhibitorsRepurposing

Substanzen

Cardiac GlycosidesSodium-Potassium-Exchanging ATPaseEnzyme Inhibitors

Autor:innen und Institutionen

  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 , Hannover, Germany.
  • Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 , Hannover, Germany. seifert.roland@mh-hannover.de.

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Evans, K., & Seifert, R. (2026). Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04443-x

Vancouver

Evans K, Seifert R. Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04443-x

BibTeX
@article{Evans2026,
  author = {Evans, Kayleigh and Seifert, Roland},
  title = {Repurposing of NKA inhibitors (‘cardiac glycosides’): a critical analysis},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04443-x}
}
Kostenlos starten →